/PRNewswire/ ISA Pharmaceuticals B.V. (ISA), a clinical-stage immunotherapy company, today announced positive anti-tumor response data with ISA101b, an.
ISA's cancer vaccine fails in ph. 2, Regeneron loses interest fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to.
-Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in Rare Ocular Cancer to be Conducted at MD Anderson Cancer Center- OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/
ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy fieldSecond SITC award this year to Professor Melief who will be honoured
/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is delighted to.
/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is delighted to.
/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to.
/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to.